Industry News
Biotechnology Industry News
Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo deal
Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo deal klahucik Fri, 02/04/2022 - 11:31
Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woes
Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woes klahucik Fri, 02/04/2022 - 09:59
UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx
UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx ntaylor Fri, 02/04/2022 - 07:58
Remote possibilities: United BioSource teams with Seqster to boost decentralized study offering
Remote possibilities: United BioSource teams with Seqster to boost decentralized study offering aarmstrong Fri, 02/04/2022 - 07:56
Pfizer’s $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies
Pfizer's $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies ntaylor Fri, 02/04/2022 - 06:54
Unity once again lays off large number of staff, narrows focus to ophthalmology assets
Unity once again lays off large number of staff, narrows focus to ophthalmology assets klahucik Thu, 02/03/2022 - 16:32
Arrowhead ‘changing horses’ for ENaC pulmonary program as phase 1/2 asset shelved
Arrowhead ‘changing horses’ for ENaC pulmonary program as phase 1/2 asset shelved aarmstrong Thu, 02/03/2022 - 12:01
Pfizer accuses former employees of ‘treachery’ in stealing trade secrets to form Regor Therapeutics
Pfizer accuses former employees of 'treachery' in stealing trade secrets to form Regor Therapeutics aarmstrong Thu, 02/03/2022 - 09:29
Roche lets go of etro, dumping phase 3 Crohn’s prospect 18 months after posting weak colitis data
Roche lets go of etro, dumping phase 3 Crohn's prospect 18 months after posting weak colitis data ntaylor Thu, 02/03/2022 - 07:37
AstraZeneca punts midphase cardiovascular prospect to startup
AstraZeneca punts midphase cardiovascular prospect to startup ntaylor Thu, 02/03/2022 - 05:32
J&J discontinues work on eczema drug, leading to $610M in impairment charges for ex-XBiotech asset
J&J discontinues work on eczema drug, leading to $610M in impairment charges for ex-XBiotech asset klahucik Wed, 02/02/2022 - 16:58
J&J’s Janssen inks $1B biobucks pact for Mersana’s ADC tech in 3 targets
J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets klahucik Wed, 02/02/2022 - 16:20
Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on track
Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track aarmstrong Wed, 02/02/2022 - 09:33
FDA puts LogicBio genome editing therapy trial on hold after 2nd infant suffers adverse event
FDA puts LogicBio genome editing therapy trial on hold after 2nd infant suffers adverse event ntaylor Wed, 02/02/2022 - 07:54
Novartis JAKs in rival to Incyte’s topical eczema drug after seeing clinical data
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data ntaylor Wed, 02/02/2022 - 05:26
Doctor groups urge Biden administration to disclose costs of federally funded clinical trials
Doctor groups urge Biden administration to disclose costs of federally funded clinical trials klahucik Tue, 02/01/2022 - 10:27
Anavex touts ‘very large’ phase 3 win for Rett syndrome drug—2 weeks after moving study’s goalposts
Anavex touts 'very large' phase 3 win for Rett syndrome drug—2 weeks after moving study's goalposts aarmstrong Tue, 02/01/2022 - 10:27
UPDATE: Anavex touts ‘very large’ phase 3 win for Rett syndrome drug—2 weeks after moving study’s goalposts
UPDATE: Anavex touts 'very large' phase 3 win for Rett syndrome drug—2 weeks after moving study's goalposts aarmstrong Tue, 02/01/2022 - 10:27
Takeda shunts jewel of Shire takeover to new spinoff Oak Hill
Takeda shunts jewel of Shire takeover to new spinoff Oak Hill ntaylor Tue, 02/01/2022 - 08:21
As CEO goes, cash woes drive Sio to give Parkinson’s program the heave-ho
As CEO goes, cash woes drive Sio to give Parkinson's program the heave-ho ntaylor Tue, 02/01/2022 - 05:19